Shopping Cart
- Remove All
- Your shopping cart is currently empty
Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $152 | In Stock | |
5 mg | $373 | In Stock | |
10 mg | $556 | In Stock | |
25 mg | $896 | In Stock | |
50 mg | $1,220 | In Stock | |
100 mg | $1,650 | In Stock | |
1 mL x 10 mM (in DMSO) | $550 | In Stock |
Description | Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability. |
Targets&IC50 | PPARγ:153.5 μM (IC50), PPARβ:102.4 μM (IC50), PPARα:92.8 μM (IC50) |
In vitro | Normal or IR L6 myotubes were incubated with Norathyriol (2.5 - 10 μM, 0.625 - 2.5 μM), mangiferin (10 - 40 μM, 2.5 - 10 μM) or rosiglitazone (20 μM) and/or 0.05 nM insulin for 24 h, respectively. The glucose consumption was assessed using the glucose oxidase method. Immunoblotting was performed to detect protein kinase B (PKB/Akt) and AMP-activated protein kinase (AMPK) phosphorylation in L6 myotubes cells. Norathyriol and mangiferin treatment alone increased the glucose consumption 61.9 and 56.3%, respectively, in L6 myotubes and made additional increasing with 0.05 nM insulin. In IR L6 myotubes, Norathyriol treatment made increasing with or without insulin, mangiferin treatment also made increasing but only when co-treated with insulin. Immunoblotting results showed that Norathyriol and mangiferin produced an increase of 1.9 - and 1.8-fold in the phosphorylation levels of the AMPK, but not in Akt[1] |
Molecular Weight | 260.2 |
Formula | C13H8O6 |
Cas No. | 3542-72-1 |
Smiles | Oc1cc(O)c2c(c1)oc1cc(O)c(O)cc1c2=O |
Relative Density. | 1.766g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 65 mg/ml (249.81 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.